other material
confidence high
sentiment positive
materiality 0.40
bioAffinity debuts CyPath Lung with AvMEDICAL at NAVREF conference to 300+ VA physicians
bioAffinity Technologies, Inc.
- bioAffinity and AvMEDICAL, a Service-Disabled Veteran-Owned Small Business, held the first joint CyPath Lung exhibition at NAVREF 2026 in Arlington, Virginia, reaching 300+ attendees.
- The VA reports about 7,700 veterans are diagnosed with lung cancer each year; the federal distribution agreement aims to expand veteran access to the noninvasive test.
- CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value in a published trial of high-risk patients with nodules under 20 mm.
- bioAffinity also presented CyPath Lung at the GO2 for Lung Cancer Centers of Excellence conference in San Diego; GO2 works with the VA and 700+ screening centers.
- The nationwide agreement uses AvMEDICAL's government contracting expertise and procurement channels; AvMEDICAL has more than doubled its product portfolio since 2020.